{"doi":"10.1161/circ.145.suppl_1.072","title":"Abstract 072: Statin Eligibility And Use For Primary Prevention Among US Adults Across Strata Of Atherosclerotic Cardiovascular Disease Risk","abstract":"<jats:p>\n            <jats:bold>Introduction:</jats:bold>\n            In 2019, primary prevention guidelines broadened consideration for statin eligibility among those at borderline to intermediate risk for atherosclerotic cardiovascular disease (ASCVD) in the presence of a risk-enhancing factor (REF). However, the proportion of US adults affected by these guidelines, particularly among those estimated to be at borderline to intermediate risk for ASCVD, is unclear.\n          </jats:p>\n          <jats:p>\n            <jats:bold>Objectives:</jats:bold>\n            To determine the contemporary prevalence of statin use and eligibility among US adults at low, borderline, intermediate, and high ten-year risk of ASCVD in the presence of ASCVD risk-enhancing factors.\n          </jats:p>\n          <jats:p>\n            <jats:bold>Methods:</jats:bold>\n            We included participants age ≥ 20 years from the National Health and Nutrition Examination Survey from 2015-2018. Ten-year ASCVD risk was classified based on the Pooled Cohort Equations as: low &lt;5%, borderline 5 - &lt;7.5%, intermediate ≥7.5 - &lt;20%, and high ≥20%. The weighted prevalence of statin use was calculated in each risk category. Weighted logistic regression assessed the association between presence of risk-enhancing factors (see Table) with statin use across strata of ASCVD risk.\n          </jats:p>\n          <jats:p>\n            <jats:bold>Results:</jats:bold>\n            Of 1350 participants (representing 37,705,137 US adults), 46% were female and mean (SE) age was 58 (0.6) years. Of these 39%, 15%, 31% and 15% were in the low, borderline, intermediate, and high ASCVD risk groups, respectively. Among adults at borderline and intermediate ASCVD risk, 89% and 90% had at least one risk-enhancing factor, respectively. Of these adults, 88% and 91% were not on a statin, respectively. Odds of statin use for individuals with risk-enhancing factors is shown in the Table.\n          </jats:p>\n          <jats:p>\n            <jats:bold>Conclusion:</jats:bold>\n            A large proportion of adults with borderline/intermediate ASCVD risk were not taking a statin despite a high prevalence of risk-enhancing factors.\n          </jats:p>","journal":"Circulation","year":2022,"id":597317,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1530269,"name":"Natalie Cameron","orcid":null,"position":1,"is_corresponding":false},{"id":1530270,"name":"Imani Bah","orcid":null,"position":2,"is_corresponding":false},{"id":1530271,"name":"Kaitlyn Beltrame","orcid":null,"position":3,"is_corresponding":false},{"id":1530273,"name":"Sadiya Khan","orcid":null,"position":4,"is_corresponding":false},{"id":1530276,"name":"Nilay S Shah","orcid":null,"position":5,"is_corresponding":false},{"id":832105,"name":"Michael M Hammond","orcid":"0000-0002-0157-4458","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Abstract 072: Statin Eligibility And Use For Primary Prevention Among US Adults Across Strata Of Atherosclerotic Cardiovascular Disease Risk","abstract":"<jats:p>\n            <jats:bold>Introduction:</jats:bold>\n            In 2019, primary prevention guidelines broadened consideration for statin eligibility among those at borderline to intermediate risk for atherosclerotic cardiovascular disease (ASCVD) in the presence of a risk-enhancing factor (REF). However, the proportion of US adults affected by these guidelines, particularly among those estimated to be at borderline to intermediate risk for ASCVD, is unclear.\n          </jats:p>\n          <jats:p>\n            <jats:bold>Objectives:</jats:bold>\n            To determine the contemporary prevalence of statin use and eligibility among US adults at low, borderline, intermediate, and high ten-year risk of ASCVD in the presence of ASCVD risk-enhancing factors.\n          </jats:p>\n          <jats:p>\n            <jats:bold>Methods:</jats:bold>\n            We included participants age ≥ 20 years from the National Health and Nutrition Examination Survey from 2015-2018. Ten-year ASCVD risk was classified based on the Pooled Cohort Equations as: low &lt;5%, borderline 5 - &lt;7.5%, intermediate ≥7.5 - &lt;20%, and high ≥20%. The weighted prevalence of statin use was calculated in each risk category. Weighted logistic regression assessed the association between presence of risk-enhancing factors (see Table) with statin use across strata of ASCVD risk.\n          </jats:p>\n          <jats:p>\n            <jats:bold>Results:</jats:bold>\n            Of 1350 participants (representing 37,705,137 US adults), 46% were female and mean (SE) age was 58 (0.6) years. Of these 39%, 15%, 31% and 15% were in the low, borderline, intermediate, and high ASCVD risk groups, respectively. Among adults at borderline and intermediate ASCVD risk, 89% and 90% had at least one risk-enhancing factor, respectively. Of these adults, 88% and 91% were not on a statin, respectively. Odds of statin use for individuals with risk-enhancing factors is shown in the Table.\n          </jats:p>\n          <jats:p>\n            <jats:bold>Conclusion:</jats:bold>\n            A large proportion of adults with borderline/intermediate ASCVD risk were not taking a statin despite a high prevalence of risk-enhancing factors.\n          </jats:p>","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W4226341323","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[{"year":2023,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://doi.org/10.1161/circ.145.suppl_1.072","host_type":"journal"}],"fields_of_study":["Cardiovascular Health and Risk Factors","Global Public Health Policies and Epidemiology"],"mesh_terms":[],"keywords":["Medicine","Statin","Atherosclerotic cardiovascular disease","Logistic regression","Internal medicine","Cohort","Risk factor","Odds","Odds ratio","Disease","National Health and Nutrition Examination Survey","Physical therapy","Demography","Environmental health","Population"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T12:56:37.051586Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}